WGS
GeneDx Holdings Corp. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -5.9% ·
share flow +17.8% ·
net new positions -12.5%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 88 | -5 | 15.43M | $1.06B | +10 | −14 |
| Q1 2026 | 95 | +2 | 15.21M | $977.50M | +14 | −13 |
| Q4 2025 | 94 | +1 | 15.07M | $1.96B | +3 | −1 |
| Q3 2025 | 16 | -1 | 7.41M | $798.15M | +2 | −4 |
| Q2 2025 | 15 | -1 | 4.67M | $430.80M | +1 | −2 |
| Q1 2025 | 13 | 0 | 2.11M | $186.46M | n/a | n/a |
| Q4 2024 | 13 | +1 | 1.90M | $146.41M | +2 | −1 |
| Q3 2024 | 11 | +4 | 1.69M | $71.81M | +4 | n/a |
| Q2 2024 | 7 | n/a | 992.14K | $25.94M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 1.53M | +6.6% | $164.74M | 0.0% | ▲ Add | 2 | SEC ↗ ×14 |
| 2 | The Vanguard Group ✦ (passive) | 1.17M | -0.9% | $126.10M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Goldman Sachs Group ✦ | 1.17M | n/a | $125.86M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 4 | Fidelity (FMR) ✦ | 503.31K | +208.2% | $54.23M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 5 | Geode Capital Management ✦ (passive) | 489.40K | +1.0% | $52.74M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Morgan Stanley ✦ | 467.81K | n/a | $50.40M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 7 | ARK Investment Management ✦ | 446.98K | New | $48.16M | 0.3% | New | 1 | SEC ↗ |
| 8 | State Street Global Advisors ✦ (passive) | 439.81K | +5.7% | $47.38M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 395.73K | -2.7% | $42.64M | 0.0% | ▼ Trim | 4 | SEC ↗ ×3 |
| 10 | T. Rowe Price ✦ | 331.41K | +2101.3% | $35.71M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Citadel Advisors ✦ | 190.94K | -29.9% | $20.57M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 12 | Two Sigma Investments ✦ | 130.43K | +6.3% | $14.05M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | JPMorgan Chase ✦ | 55.59K | n/a | $5.99M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 14 | Millennium Management ✦ | 51.74K | New | $5.57M | 0.0% | New | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 28.74K | +21.2% | $3.10M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 16 | Marshall Wace ✦ | 8.49K | -33.1% | $914,497 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| ARK Investment Management | $48.16M | 0.3% |
| Millennium Management | $5.57M | 0.0% |
Exited
| Norges Bank | $6.28M | was 0.0% |
| Point72 Asset Management | $4.85M | was 0.0% |
| D. E. Shaw & Co. | $845,098 | was 0.0% |
| Gotham Asset Management | $414,841 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 240 holders, 31.22M shares, $1.98B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 3.04K sh · $300,846
Officer · 1.08K sh · $106,816
Officer, Director · 1.65K sh · $155,337
Officer, Director · 148 sh · $14,120
Officer, Director · 1.52K sh · $147,774
Officer, Director · 4.14K sh · $406,936
Officer · 586 sh · $55,235
Officer · 52 sh · $4,961
Officer · 541 sh · $52,423
Officer · 1.47K sh · $144,457
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
1.8% of class · View original SEC filing ↗